Department of Defense Pharamacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9402-25-Q-9303

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

San Antonio, Texas, UNITED STATES

SourceSAM
The Department of Defense (DoD), through the Defense Health Agency, has issued a solicitation (Procurement Identifier: HT9402-25-Q-9303) for the establishment of Blanket Purchase Agreements (BPAs) and participation in the Uniform Formulary Additional Discount Program (UF ADP) as part of its ongoing efforts to maintain an effective, efficient, and integrated pharmacy benefits program for the Military Health System (MHS). This initiative is mandated by 10 U.S.C. § 1074g and further detailed in 32 CFR Section 199.21, which require the DoD to evaluate and select pharmaceutical agents for inclusion in the DoD Uniform Formulary (UF) based on clinical and cost effectiveness. The scope of this procurement centers on the acquisition of pharmaceutical agents within specific drug classes identified for potential placement on the UF. The process is closely tied to the recommendations of the DoD Pharmacy and Therapeutics (P&T) Committee, which reviews the clinical and cost profiles of drugs in each therapeutic class. For the August 2025 P&T Committee meeting, the following newly approved drugs will be considered: Hemiclor (Diuretics), Symbravo (Migraine Agents - Triptans), umeclidinium-vilanterol (Pulmonary-2 Agents for Chronic Obstructive Pulmonary Disease), ustekinumab (Targeted Immunomodulatory Biologics - IL-23), and Vyvgart Hytrulo (Miscellaneous Neurological Agents). Contractors are invited to submit quotations for these pharmaceutical agents in accordance with the instructions provided in the attached RFQ. The RFQ outlines the requirements for both the UF BPA and UF ADP agreements, including the necessary documentation, deadlines, and evaluation criteria. Key deliverables include competitive pricing proposals and responses to clinical questions, which must be submitted via email to the designated point of contact by the specified deadline. The place of performance for this contract is San Antonio, Texas, and the opportunity is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505. The contracting entity is the Defense Health Agency, a federal office responsible for administering the MHS pharmacy benefits program. Interested parties should note the following important dates and procedural requirements: - A pre-quotation teleconference is scheduled for June 4, 2025, with details provided in Part 2.4 of the RFQ. - Responses to clinical questions (Part 3.4) must be submitted via email to the RFQ point of contact listed in Part 2.3.1, no later than the date specified in Part 2.3.2. - The official response deadline for quotations is June 20, 2025, at 17:06. Primary and secondary points of contact for this solicitation are Tracy Banks ([email protected]) and Julianne Canaley ([email protected]), respectively. Additional details, instructions, and appendices are available through the solicitation notice on SAM.gov (Opportunity ID: fb6a3302b5564ed38a0209c8c0711346). This procurement represents a significant opportunity for pharmaceutical manufacturers with capabilities in the specified drug classes to contribute to the DoD’s pharmacy benefits program. The requirements and objectives are focused on ensuring the availability of clinically effective and cost-efficient pharmaceutical agents for military beneficiaries, with a transparent and competitive selection process governed by federal regulations and the recommendations of the P&T Committee. Contractors should carefully review the RFQ and associated documents to ensure compliance with all submission requirements and deadlines.
Documents10